FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596728500> ?p ?o ?g. }

• W2596728500 endingPage "93" @default.
• W2596728500 startingPage "84" @default.
• W2596728500 abstract "Tryptamines have emerged as new psychoactive substances (NPS), which are distributed and consumed recreationally without preclinical studies or safety tests. Within the alpha-methylated tryptamines, some of the psychoactive effects of the prototypical alpha-methyltryptamine (AMT) have been described decades ago and a contributing factor of its acute toxicity appears to involve the inhibition of monoamine oxidase (MAO). However, detailed information about analogs is scarce. Therefore, thirteen AMT analogs were investigated for their potential to inhibit MAO. An in vitro assay analyzed using hydrophilic interaction liquid chromatography-high resolution-tandem mass spectrometry was developed and validated. The AMT analogs were incubated with recombinant human MAO-A or B and kynuramine, a non-selective MAO substrate to determine the IC50 values. The known MAO-A inhibitors 5-(2-aminopropyl)indole (5-IT), harmine, harmaline, yohimbine, and the MAO-B inhibitor selegiline were tested for comparison. AMT and all analogs showed MAO-A inhibition properties with IC50 values between 0.049 and 166μM, whereas four analogs inhibited also MAO-B with IC50 values between 82 and 376μM. 7-Me-AMT provided the lowest IC50 value against MAO-A comparable to harmine and harmaline and was identified as a competitive MAO-A inhibitor. Furthermore, AMT, 7-Me-AMT, and nine further analogs inhibited MAO activity in human hepatic S9 fraction used as model for the human liver which expresses both isoforms. The obtained results suggested that MAO inhibition induced by alpha-methylated tryptamines might be clinically relevant concerning possible serotonergic and adrenergic effects and interactions with drugs (of abuse) particularly acting as monoamine reuptake inhibitors. However, as in vitro assays have only limited conclusiveness, further studies are needed." @default.
• W2596728500 created "2017-03-23" @default.
• W2596728500 creator A5005457342 @default.
• W2596728500 creator A5005967499 @default.
• W2596728500 creator A5006156563 @default.
• W2596728500 creator A5011396262 @default.
• W2596728500 creator A5078935928 @default.
• W2596728500 date "2017-04-01" @default.
• W2596728500 modified "2023-10-07" @default.
• W2596728500 title "In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks" @default.
• W2596728500 cites W1532405549 @default.
• W2596728500 cites W1596498585 @default.
• W2596728500 cites W1597304195 @default.
• W2596728500 cites W1631511813 @default.
• W2596728500 cites W1899847589 @default.
• W2596728500 cites W1977861475 @default.
• W2596728500 cites W1982064932 @default.
• W2596728500 cites W1998621094 @default.
• W2596728500 cites W2001030322 @default.
• W2596728500 cites W2004686192 @default.
• W2596728500 cites W2018957682 @default.
• W2596728500 cites W2037956209 @default.
• W2596728500 cites W2046909794 @default.
• W2596728500 cites W2048561267 @default.
• W2596728500 cites W2059820434 @default.
• W2596728500 cites W2063875549 @default.
• W2596728500 cites W2074420273 @default.
• W2596728500 cites W2074631079 @default.
• W2596728500 cites W2078638048 @default.
• W2596728500 cites W2079486654 @default.
• W2596728500 cites W2080602223 @default.
• W2596728500 cites W2118285308 @default.
• W2596728500 cites W2121625436 @default.
• W2596728500 cites W212243276 @default.
• W2596728500 cites W2123778879 @default.
• W2596728500 cites W2128128745 @default.
• W2596728500 cites W2168207691 @default.
• W2596728500 cites W2198168203 @default.
• W2596728500 cites W2209408218 @default.
• W2596728500 cites W2423462655 @default.
• W2596728500 cites W2468719307 @default.
• W2596728500 cites W2522590875 @default.
• W2596728500 cites W4229753311 @default.
• W2596728500 cites W974037284 @default.
• W2596728500 doi "https://doi.org/10.1016/j.toxlet.2017.03.007" @default.
• W2596728500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28302559" @default.
• W2596728500 hasPublicationYear "2017" @default.
• W2596728500 type Work @default.
• W2596728500 sameAs 2596728500 @default.
• W2596728500 citedByCount "20" @default.
• W2596728500 countsByYear W25967285002017 @default.
• W2596728500 countsByYear W25967285002018 @default.
• W2596728500 countsByYear W25967285002019 @default.
• W2596728500 countsByYear W25967285002020 @default.
• W2596728500 countsByYear W25967285002021 @default.
• W2596728500 countsByYear W25967285002022 @default.
• W2596728500 countsByYear W25967285002023 @default.
• W2596728500 crossrefType "journal-article" @default.
• W2596728500 hasAuthorship W2596728500A5005457342 @default.
• W2596728500 hasAuthorship W2596728500A5005967499 @default.
• W2596728500 hasAuthorship W2596728500A5006156563 @default.
• W2596728500 hasAuthorship W2596728500A5011396262 @default.
• W2596728500 hasAuthorship W2596728500A5078935928 @default.
• W2596728500 hasBestOaLocation W25967285002 @default.
• W2596728500 hasConcept C114461151 @default.
• W2596728500 hasConcept C126322002 @default.
• W2596728500 hasConcept C170493617 @default.
• W2596728500 hasConcept C181199279 @default.
• W2596728500 hasConcept C185592680 @default.
• W2596728500 hasConcept C202751555 @default.
• W2596728500 hasConcept C2776024655 @default.
• W2596728500 hasConcept C2776134090 @default.
• W2596728500 hasConcept C2776885963 @default.
• W2596728500 hasConcept C2777135210 @default.
• W2596728500 hasConcept C2777676773 @default.
• W2596728500 hasConcept C2777752497 @default.
• W2596728500 hasConcept C2779134260 @default.
• W2596728500 hasConcept C2779734285 @default.
• W2596728500 hasConcept C2780560928 @default.
• W2596728500 hasConcept C2781450507 @default.
• W2596728500 hasConcept C2909645108 @default.
• W2596728500 hasConcept C39398028 @default.
• W2596728500 hasConcept C55493867 @default.
• W2596728500 hasConcept C71924100 @default.
• W2596728500 hasConcept C86803240 @default.
• W2596728500 hasConcept C98274493 @default.
• W2596728500 hasConceptScore W2596728500C114461151 @default.
• W2596728500 hasConceptScore W2596728500C126322002 @default.
• W2596728500 hasConceptScore W2596728500C170493617 @default.
• W2596728500 hasConceptScore W2596728500C181199279 @default.
• W2596728500 hasConceptScore W2596728500C185592680 @default.
• W2596728500 hasConceptScore W2596728500C202751555 @default.
• W2596728500 hasConceptScore W2596728500C2776024655 @default.
• W2596728500 hasConceptScore W2596728500C2776134090 @default.
• W2596728500 hasConceptScore W2596728500C2776885963 @default.
• W2596728500 hasConceptScore W2596728500C2777135210 @default.
• W2596728500 hasConceptScore W2596728500C2777676773 @default.
• W2596728500 hasConceptScore W2596728500C2777752497 @default.

• next